Spyre Therapeutics, Inc. (SYRE)
NASDAQ: SYRE · Real-Time Price · USD
79.90
-0.20 (-0.25%)
At close: Oct 16, 2026, 4:00 PM EDT
78.90
-1.00 (-1.25%)
After-hours: Oct 16, 2026, 7:59 PM EDT
Spyre Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
125
Market Cap
7.47B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | 886.00K | -1.44M | -61.96% |
| Dec 31, 2022 | 2.33M | -16.41M | -87.57% |
| Dec 31, 2021 | 18.74M | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Caris Life Sciences | 989.61M |
| Ionis Pharmaceuticals | 874.09M |
| TG Therapeutics | 799.54M |
| Axsome Therapeutics | 776.57M |
| Arrowhead Pharmaceuticals | 669.50M |
| Twist Bioscience | 431.80M |
| Protagonist Therapeutics | 281.99M |
| Kymera Therapeutics | 105.00M |
SYRE News
- 6 days ago - Spyre Therapeutics initiated with a Buy at UBS - TheFly
- 11 days ago - Spyre Therapeutics falls -12.8% - TheFly
- 11 days ago - Spyre Therapeutics falls -8.4% - TheFly
- 12 days ago - Spyre Therapeutics 4.12M share Spot Secondary priced at $85.00 - TheFly
- 12 days ago - Spyre Therapeutics Announces Pricing of $350.0 Million Public Offering of Common Stock - GlobeNewsWire
- 12 days ago - Spyre Therapeutics $250M Spot Secondary; re-offered at $85.00 per share - TheFly
- 12 days ago - Spyre Therapeutics announces common stock offering, no amount given - TheFly
- 12 days ago - Spyre Therapeutics Announces Proposed Public Offering of its Common Stock - GlobeNewsWire